Skip to main content
Eurobio Scientific logo

Eurobio Scientific — Investor Relations & Filings

Ticker · ALERS ISIN · FR0013240934 LEI · 969500IQEUEH806GE257 PA Manufacturing
Open in API
Filings indexed 198 across all filing types
Latest filing 2025-05-19 Major Shareholding Noti…
Country FR France
Listing PA ALERS

About Eurobio Scientific

https://www.eurobio-scientific.com

Eurobio Scientific is an integrated company specializing in in vitro diagnostics (IVD). Its activities cover the entire value chain, from research and development to the manufacturing and commercialization of specialty diagnostic products. The company's core focus areas are transplantation, oncology, and infectious diseases. In transplantation, it provides reagents, software for transplant matching and chimerism monitoring, and culture media for cornea grafts. For oncology, it develops and manufactures prognostic genomic tests for breast and prostate cancer. The group also markets a comprehensive portfolio of molecular tests for detecting infectious diseases, alongside solutions for immunology, fertility, and dermatological conditions.

Recent filings

Filing Released Lang Actions
Eurobio Scientific : EB Development franchit à la hausse le seuil de 90%
Major Shareholding Notification Classification · 99% confidence The document is titled "COMMUNIQUE DE PRESSE" (Press Release) and announces a specific corporate event: EB Development crossing the 90% ownership threshold in Eurobio Scientific. This type of announcement, detailing changes in significant share ownership, directly corresponds to the Major Shareholding Notification category. The document is short (2512 characters) and serves as an immediate notification rather than a comprehensive report. Therefore, the most appropriate classification is Major Shareholding Notification (MRQ).
2025-05-19 French
Eurobio Scientific: EB Development rises above 90% threshold
Major Shareholding Notification Classification · 98% confidence The document announces that EB Development has crossed the 90% threshold of Eurobio Scientific's share capital and voting rights due to market acquisitions. This directly relates to a change in significant share ownership, as crossing major thresholds (like 5%, 10%, 33.3%, 50%, 66.6%, 90%) requires mandatory notification. The document also mentions the upcoming Annual General Meeting date, but the primary focus and news headline is the shareholding change. This fits the definition of 'Major Shareholding Notification' (MRQ). It is not a Director's Dealing (DIRS) as it concerns a corporate entity (EB Development) crossing the threshold, not an individual director's personal transaction, nor is it a general regulatory filing (RNS) given the specific nature of the announcement.
2025-05-19 English
Eurobio Scientific: MISE À DISPOSITION DU RAPPORT FINANCIER ANNUEL 2024
Audit Report / Information Classification · 98% confidence The document is a short press release (2580 characters) titled "MISE À DISPOSITION DU RAPPORT FINANCIER ANNUEL 2024" (Making available of the 2024 Annual Financial Report). It explicitly states that the company has made its annual financial report available to the public and filed it with the AMF (Autorité des Marchés Financiers) on April 29, 2025. It directs the reader to the website to consult the report. According to Rule #2 (The "MENU VS MEAL" Rule), a short announcement stating that a report has been published or made available, without containing the full report content, should be classified as a Report Publication Announcement (RPA). Although it concerns the Annual Financial Report, the document itself is the announcement of its availability, not the 10-K filing itself. FY 2024
2025-04-29 French
Eurobio Scientific : RESULTAT ANNUEL 2024 - Croissance du cœur d’activité et déploiement stratégique
Earnings Release Classification · 100% confidence The document is titled "COMMUNIQUE DE PRESSE" and presents "RESULTAT ANNUEL 2024" (Annual Results 2024). It contains detailed consolidated financial tables comparing 2024 results to 2023, including revenue, gross margin, EBITDA, and net result. This structure is characteristic of an Earnings Release (ER) or a section of a larger annual report detailing results. Since it is a press release summarizing the full-year financial performance, it fits the definition of an Earnings Release (ER) which provides initial announcements of periodical financial results (key highlights only), even though it contains significant detail. It is not the full 10-K, nor is it a short announcement merely pointing to a report (RPA/RNS). The presence of the next financial event, the 'Assemblée générale : 19 juin 2025', confirms this is a results announcement. FY 2024
2025-04-28 French
Eurobio Scientific: 2024 annual results
Earnings Release Classification · 100% confidence The document is explicitly titled "2024 ANNUAL RESULTS" and contains detailed consolidated financial tables for the years 2024 and 2023, including Revenue, Gross Margin, EBITDA, Net Income, and Free Cash Flow analysis. This content structure is characteristic of a comprehensive annual financial report. Although it is presented as a 'PRESS RELEASE', the depth and scope of the financial data strongly indicate it is the primary disclosure of the full-year results, which aligns best with the Annual Report (10-K) definition, even if it's a press release version of the underlying annual filing data. The document also mentions the upcoming 'Annual General Meeting: June 19, 2025', confirming the context is the conclusion of the fiscal year. FY 2024
2025-04-28 English
EUROBIO SCIENTIFIC ÉTEND SA PRÉSENCE EN ITALIE
M&A Activity Classification · 99% confidence The document is a press release dated March 12, 2025, announcing several corporate actions: the acquisition of Voden Medical Instruments Spa's Life Science unit, the finalization of the acquisition of Quimark SRL, and the cessation of a supplier relationship (T2 Biosystems). These events relate to corporate structure changes, M&A activity, and operational updates. Since the document details specific transactions (acquisitions) and significant operational changes, it falls under the category of corporate actions. While it touches upon M&A (TAR), it is primarily a broad announcement of strategic business developments, including financing (cash and bank loan mentioned for one acquisition) and operational impacts. Given the options, 'Capital/Financing Update' (CAP) covers fundraising aspects, and 'M&A Activity' (TAR) covers the acquisitions. However, the document is a general corporate announcement detailing strategic moves, including acquisitions and supplier termination. In the context of standard filings, a press release detailing acquisitions and strategic shifts is often classified broadly. Since the primary focus is on acquisitions (M&A), TAR is a strong candidate. However, the document also details financing for the acquisition and the impact of a supplier leaving, making it a broader strategic update. Given the explicit mention of 'acquisition' and the nature of the announcement, TAR (M&A Activity) is the most fitting specific category for the primary events described, although it is not a formal regulatory filing like a 10-K or IR. Since it is a press release announcing strategic corporate transactions, and TAR specifically covers merger proposals or takeover bids (which acquisitions fall under), I will select TAR. The document length is short (3899 chars), but it is the content itself, not an announcement *of* another report, so RPA/RNS is not appropriate.
2025-03-12 French

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.